Skip to main content

Table 2 The relation between HbA1c and risk for new cardiovascular events or mortality in the whole cohort and in quartiles stratified by vascular risk

From: The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease

 

Whole cohort

Q1

Q2

Q3

Q4

 

n = 1096

n = 274

n = 274

n = 274

n = 274

SMART risk score (% 10 year risk for recurrent vascular events)

 

5–16

16–24

24–37

37–100

All-cause mortality

243 events

21 events

39 events

66 events

117 events

Model I

1.13 (1.02–1.24)

1.42 (0.99–2.04)

1.11 (0.90–1.37)

1.00 (0.82–1.22)

1.23 (1.04–1.46)

Model II

1.21v (1.09–1.34)

1.57 (1.10–2.25)

1.09 (0.87–1.36)

1.04 (0.85–1.27)

1.28 (1.08–1.53)

Model III

1.18 (1.06–1.31)

1.36 (0.93–1.98)

1.04 (0.82–1.33)

1.00 (0.80–1.24)

1.33 (1.11–1.60)

Composite vascular outcome

223 events

28 events

46 events

53 events

96 events

Model I

1.03 (0.92–1.15)

1.23 (0.89–1.70)

0.89 (0.70–1.14)

0.90 (0.71–1.13)

1.18 (0.98–1.42)

Model II

1.07 (0.96–1.20)

1.31 (0.94–1.83)

0.93 (0.73–1.20)

0.94 (0.74–1.19)

1.19 (0.99–1.43)

Model III

1.03 (0.91–1.16)

1.17 (0.83–1.67)

0.92 (0.71–1.20)

0.88 (0.68–1.15)

1.20 (0.99–1.46)

Myocardial infarction

84 events

15 events

23 events

23 events

23 events

Model I

0.88 (0.72–1.08)

0.86 (0.50–1.49)

0.70 (0.47–1.06)

0.94 (0.70–1.32)

1.02 (0.68–1.53)

Model II

0.88 (0.72–1.09)

0.87 (0.50–1.52)

0.71 (0.47–1.08)

0.99 (0.70–1.40)

0.99 (0.66–1.49)

Model III

0.87 (0.71–1.07)

0.92 (0.51–1.65)

0.71 (0.46–1.10)

1.01 (0.69–1.48)

0.99 (0.66–1.47)

Ischemic stroke

48 events

5 events

10 events

9 events

24 events

Model I

1.10 (0.88–1.39)

1.57 (0.81–3.01)

1.09 (0.70–1.70)

0.66 (0.34–1.29)

1.25 (0.88–1.79)

Model II

1.16 (0.92–1.48)

1.72 (0.87–3.40)

1.22 (0.77–1.95)

0.64 (0.33–1.25)

1.27 (0.89–1.83)

Model III

1.09 (0.84–1.41)

2.13 (0.79–5.75)

1.28 (0.77–2.13)

0.60 (0.31–1.19)

1.26 (0.86–1.85)

Cardiovascular mortality

140 events

11 events

22 events

30 events

77 events

Model I

1.07 (0.94–1.23)

1.41 (0.85–2.35)

0.91 (0.64–1.29)

0.97 (0.72–1.30)

1.21 (0.98–1.49)

Model II

1.15 (1.00–1.32)

1.62 (1.00–2.62)

0.92 (0.64–1.31)

1.00 (0.74–1.34)

1.24 (1.00–1.54)

Model III

1.09 (0.94–1.27)

0.97 (0.59–1.60)

0.79 (0.52–1.21)

0.94 (0.67–1.31)

1.29 (1.03–1.61)

  1. The relation between HbA1c and risk for each outcome under study is represented separately. Model I is the crude model, Model II is adjusted for sex and age, and Model III is additionally adjusted for current smoking, non-HDL cholesterol, diabetes duration, systolic blood pressure and eGFR (MDRD). The hazard ratios are given per 1 % HbA1c. For example, in the patients of this cohort a 1 % higher HbA1c is associated with a 1.18-fold higher risk of all-cause mortality
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840